Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bernhard Nocht Institute of Tropical Medicine, Hamburg
Proteasome inhibitor blocks exoerythrocytic/erythrocytic Plasmodium development
October 26th, 2005
A proteasome inhibitor blocks exoerythrocytic and erythrocytic Plasmodium development. "Protein degradation is regulated during the cell cycle of all eukaryotic cells and is mediated by the ubiquitin-proteasome pathway. "Potent and specific peptide-derived inhibitors of the 20S proteasome have been developed recently as anticancer agents, based on their ability to induce apoptosis in rapidly dividing cells," scientists in Germany report. "Here, we tested a novel small molecule dipeptidyl boronic acid proteasome inhibitor, named MLN-273 on blood and liver stages of Plasmodium species, both of which undergo active...
Source: Elder Law Weekly (2005-10-26)
|
